Oglufanide
Peptideexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Feb 1, 1999 (NCT00003773)
Timeline
Indications
Mechanism of action
- UnclearImmunity, active
Unclear immunity, active
Chemistry & pharmacology
Loading structure…
SMILES
N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O- Mol. weight
- 333.34 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2111029 ↗
- ChEMBLCHEMBL2107123 ↗
Also known as
- alpha-glutamyltryptophan
- alpha-glutamyltryptophan
- alpha-glutamyltryptophan
- glufanide disodium
- glufanide disodium
- glutamyltryptophan
- glutamyltryptophan
- glu-trp
- im862
- im862
- im862
- im 862 dipeptide
- l-alpha-glutamyl-l-tryptophan
- l-glu-l-trp
- l-glu-l-trp
- l-glu-l-trp
- l-glutamyl-l-tryptophan
- l-glutamyl-l-tryptophan
- l-glutamyl-l-tryptophan
- l-α-glu-l-trp
- l-α-glu-l-trp
- oglufanide
- oglufanide
- oglufanide
- oglufanide disodium
- oglufanide disodium
- oglufanide disodium
- thymogen
- α-glu-trp
- α-glu-trp
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00017303 | Phase 2 | Jan 1, 2001 | Cytran |
| NCT00002445 | Phase 3 | Nov 2, 1999 | Cytran |
| NCT00006037 | Phase 2 | Nov 1, 1999 | National Cancer Institute (NCI), University of Southern California |
| NCT00003773 | Phase 1 | Feb 1, 1999 | National Cancer Institute (NCI), University of Southern California |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cytran | For profit | 2 | 2 | 2 | 1999 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 1999 |
| University of Southern California | Academic/Hospital | 2 | 2 | 2 | 1999 |
3 organizations
Page 1 / 1